| scholarly article | Q13442814 |
| P2093 | author name string | Ramola Sane | |
| Rajendar K. Mittapalli | |||
| William F. Elmquist | |||
| Shruthi Vaidhyanathan | |||
| P2860 | cites work | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 |
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases | Q28250795 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. | Q33339438 | ||
| Blood-brain barrier active efflux transporters: ATP-binding cassette gene family | Q33985133 | ||
| Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux | Q34028148 | ||
| The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain | Q34458602 | ||
| Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. | Q35048738 | ||
| Systematic review of medical treatment in melanoma: current status and future prospects. | Q35584299 | ||
| Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout Mice | Q35996449 | ||
| Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features | Q37036930 | ||
| Targeting the RAS pathway in melanoma | Q37137004 | ||
| Targeting BRAF in advanced melanoma: a first step toward manageable disease | Q37859164 | ||
| Determinants of outcome in melanoma patients with cerebral metastases | Q38517839 | ||
| P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib | Q39843608 | ||
| DTIC (NSC-45388) in malignant melanoma: a perspective | Q40496210 | ||
| Demographics of brain metastasis. | Q41123955 | ||
| An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin | Q46213823 | ||
| P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan | Q46920680 | ||
| Vemurafenib for Melanoma Metastases to the Brain | Q48763254 | ||
| Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 | ||
| BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma | Q58024751 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 33-40 | |
| P577 | publication date | 2012-03-27 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) | |
| Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032) | |||
| P478 | volume | 342 |
| Q90083275 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein |
| Q35820476 | A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. |
| Q38763312 | A systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from January 2001 to October 2015. |
| Q35171274 | ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors |
| Q38887917 | ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors. |
| Q36251418 | Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models |
| Q64967468 | Alterations in Expression and Function of ABC Family Transporters at Blood-Brain Barrier under Liver Failure and Their Clinical Significances. |
| Q96761995 | Assessing OATP1B1- and OATP1B3-mediated drug-drug interaction potential of vemurafenib using R-value and physiologically based pharmacokinetic models |
| Q35317533 | Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression |
| Q54977694 | BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. |
| Q37090142 | BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis |
| Q58776439 | BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors |
| Q36654999 | BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation |
| Q57176317 | Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine |
| Q38156192 | Biology in prevention and treatment of brain metastases |
| Q28829017 | Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases |
| Q50043573 | Brain distribution of a novel MEK inhibitor E6201: implications in the treatment of melanoma brain metastases |
| Q39331752 | Challenges in the delivery of therapies to melanoma brain metastases |
| Q57284517 | Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report |
| Q39159365 | Clinical Pharmacokinetics of Vemurafenib |
| Q56673276 | Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter |
| Q33888789 | Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts |
| Q41651512 | Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats |
| Q47573654 | Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? |
| Q48151074 | Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2 |
| Q35799917 | Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. |
| Q36186193 | Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model |
| Q28580899 | Evaluation of intestinal absorption of amtolmetin guacyl in rats: Breast cancer resistant protein as a primary barrier of oral bioavailability |
| Q36503052 | Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases |
| Q33942964 | Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases |
| Q38187646 | Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. |
| Q46105334 | Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib |
| Q35916658 | Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. |
| Q38351134 | Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier |
| Q48618698 | Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib |
| Q46041746 | Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar |
| Q50857354 | Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas |
| Q37431085 | Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib |
| Q44959749 | Management of intracranial melanomas in the era of precision medicine |
| Q30251581 | Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy |
| Q36642420 | Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases |
| Q31098294 | Melanoma brain metastases : Treatment options |
| Q36512866 | Melanoma brain metastases and vemurafenib: need for further investigation |
| Q38764364 | Molecular insights into melanoma brain metastases |
| Q48301559 | Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. |
| Q36556926 | Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells |
| Q37276052 | P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model |
| Q50026347 | Pharmacokinetic assessment of cooperative efflux of the multi-targeted kinase inhibitor ponatinib across the blood-brain barrier |
| Q38044958 | Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure |
| Q48217300 | Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance |
| Q39140289 | Renal Drug Transporters and Drug Interactions |
| Q36717122 | Saturable Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier Leads to Nonlinear Distribution of Elacridar to the Central Nervous System |
| Q30664269 | Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data |
| Q38207943 | Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics |
| Q47093947 | Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib |
| Q48234725 | Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. |
| Q30239901 | Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma |
| Q38715328 | Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors |
| Q64118762 | Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature |
| Q47861254 | Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma |
| Q38233105 | Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. |
| Q37231972 | Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q39303731 | The Role of a Basolateral Transporter in Rosuvastatin Transport and Its Interplay with Apical Breast Cancer Resistance Protein in Polarized Cell Monolayer Systems |
| Q47247953 | The biology and therapeutic management of melanoma brain metastases |
| Q38454659 | Toward precision medicine in glioblastoma: the promise and the challenges |
| Q61449489 | Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis |
| Q41951346 | Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat. |
| Q38975455 | Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. |
| Q44534087 | Vemurafenib and radiation therapy in melanoma brain metastases |
| Q38040456 | Vemurafenib: in unresectable or metastatic melanoma |
Search more.